近年来，胰高血糖素样肽-1（GLP-1）受体激动剂被广泛用于肥胖治疗，并取得了良好的效果。 Survodutide是一种新型的胰高血糖素受体（GCGR）和胰高血糖素样肽-1受体（GLP-1R）双靶激动剂 ...

In addition to impaired insulin secretion, type 2 diabetic patients also have elevated levels of glucagon, which worsens hyperglycemia by increasing glucose production by the liver. Type 2 ...

Recent advances in glucagon receptor (GCGR) agonists show promise for enhancing catabolic metabolism, but concerns persist. Potential side effects include increased heart rates, hepatic glucose ...

and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of 2024. “Clearance of the IND for DA-1726 allows us to ...

glucagon receptor (GCGR), and glucose-dependent insulinotropic polypeptide (GIP) receptor. It is believed that through these interactions, Retatrutide might influence glucose and lipid metabolism ...

and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus ...